Induced Adult Refractory Active Crohn’s Disease Clinical Relieving by Using Thalidomide

Overview

With the development and application of biological agents, the treatment effect was considerable degree improvement on refractory corn's disease. However, there are quite a part of the CD patients lost response during treatment of using response. Moreover, due to various reasons, there still a lot limited on the using of biological agents in China, that make quite a part of the refractory CD patients lack of further medical treatment options. There has been a RCT study which prove that thalidomide effect and safety on treating refractory CD or who were lost response by using biological agents in Italy, but the object of study is only limited in children and adolescents. There are some small sample studies also confirmed the efficacy and safety on refractory corn's disease by using thalidomide, but need more RCT evidence.

Full Title of Study: “Induced Adult Refractory Active Crohn’s Disease Clinical Relieving by Using Thalidomide: A Randomized, Double-blind, Placebo-controlled Multicenter Clinical Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: October 2018

Detailed Description

It will be divided two groups of patients by using randomized, double-blind. One group was treated by thalidomide, the other was placebo. It will be unlocked blind and analysis the effect and safety about thalidomide after 8 weeks. The second, patients still use thalidomide after unlock blind to prove its longtime treatment effect and safety.

Interventions

  • Drug: Thalidomide
  • Drug: placebo(for thalidomide)
    • sugar pill manufactured to mimic thalidomide 100mg tablet

Arms, Groups and Cohorts

  • Experimental: thalidomide
    • thalidomide 100mg tablet by mouth, every night for 8 weeks
  • Active Comparator: placebo
    • placebo (for thalidomide) 100mg tablet by mouth, every night for 8 weeks

Clinical Trial Outcome Measures

Primary Measures

  • difference CDAI between thalidomide group and placebo group
    • Time Frame: 8 weeks
    • CDAI means Crohn’s Disease Activity Index.The purpose of this crohn’s disease activity index (CDAI) calculator is to gauge the progress or lack of progress for people with crohn’s disease. The reference article says “generally speaking, CDAI scores below 150 indicate a better prognosis than higher scores.”
  • difference SES-CD score between thalidomide group and placebo group
    • Time Frame: 8weeks
    • SES-CD means Simple endoscopic score for Crohn’s disease ,which predicts long-term prognosis in Crohn’s disease patients with clinical remission.

Secondary Measures

  • difference CDAI between different thalidomide dosage group
    • Time Frame: 1 year
    • CDAI means Crohn’s Disease Activity Index.The purpose of this crohn’s disease activity index (CDAI) calculator is to gauge the progress or lack of progress for people with crohn’s disease. The reference article says “generally speaking, CDAI scores below 150 indicate a better prognosis than higher scores.”
  • difference SES-CD score between different thalidomide dosage group
    • Time Frame: 1 year
    • SES-CD means Simple endoscopic score for Crohn’s disease ,which predicts long-term prognosis in Crohn’s disease patients with clinical remission.

Participating in This Clinical Trial

Inclusion Criteria

  • Age 18-50 years old – Diagnosis of patients with CD – Disease in the activity: CDA Ⅰ > 150 points, endoscopic see active lesions – Refractory: immunosuppressive drugs or biological agents which are used in current treatment is invalid and/or intolerance Exclusion Criteria:

  • Fiber stenosis caused by gastrointestinal obstruction symptoms – Fistula exclude anal fistula – Pregnancy or lactation – Period of women have fertility program during the study – Treatment not foot eight weeks after last IFX – Central or peripheral nerve disease – Abnormal in liver and renal function – Heart function failure – Malignant tumor – Active tuberculosis

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Sixth Affiliated Hospital, Sun Yat-sen University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Xiang Gao, Clinical Professor – Sixth Affiliated Hospital, Sun Yat-sen University
  • Overall Official(s)
    • Xiang gao, MD, Study Chair, Sixth Affiliated Hospital, Sun Yat-sen University
  • Overall Contact(s)
    • Xiang Peng, MM, 18302076916, stefaniepx@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.